NEW YORK, NY / ACCESSWIRE / June 28, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
AXSM Shareholders Click Here: https://www.zlk.com/pslra-1/axsome-therapeutics-inc-information-request-form?prid=29303&wire=1
TDOC Shareholders Click Here: https://www.zlk.com/pslra-1/teladoc-health-inc-loss-submission-form?prid=29303&wire=1
UL Shareholders Click Here: https://www.zlk.com/pslra-1/unilever-plc-loss-submission-form?prid=29303&wire=1
* ADDITIONAL INFORMATION BELOW *
Axsome Therapeutics, Inc. (NASDAQ:AXSM)
AXSM Lawsuit on behalf of: investors who purchased December 30, 2019 – April 22, 2022
Lead Plaintiff Deadline : July 12, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/axsome-therapeutics-inc-information-request-form?prid=29303&wire=1
According to the filed complaint, during the class period, Axsome Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Axsome’s chemistry, manufacturing, and control (“CMC”) practices were deficient with respect to AXS-07, the Company’s medicine for the acute treatment of migraine, and its manufacturing process; (ii) as a result, Axsome was unlikely to submit the AXS-07 New Drug Application (“NDA”) on its initially represented timeline; (iii) the foregoing CMC issues remained unresolved at the time that the U.S. Food and Drug Administration (“FDA”) reviewed the AXS-07 NDA; (iv) accordingly, the FDA was unlikely to approve the AXS-07 NDA; (v) as a result of all the foregoing, Axsome had overstated AXS-07’s regulatory and commercial prospects; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Teladoc Health, Inc. (NYSE:TDOC)
TDOC Lawsuit on behalf of: investors who purchased October 28, 2021 – April 27, 2022
Lead Plaintiff Deadline : August 5, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/teladoc-health-inc-loss-submission-form?prid=29303&wire=1
According to the filed complaint, during the class period, Teladoc Health, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) increased competition, among other factors, was negatively impacting Teladoc’s BetterHelp and chronic care businesses; (ii) accordingly, the growth of those businesses was less sustainable than Defendants had led investors to believe; (iii) as a result, Teladoc’s revenue and adjusted EBITDA projections for FY 2022 were unrealistic; (iv) as a result of all the foregoing, Teladoc would be forced to recognize a significant non-cash goodwill impairment charge; and (v) as a result, the Company’s public statements were materially false and misleading at all relevant times.
Unilever PLC (NYSE:UL)
This lawsuit is on behalf of all persons who purchased or otherwise acquired Unilever American Depositary Receipts between September 2, 2020 and July 21, 2021, inclusive.
Lead Plaintiff Deadline : August 15, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/unilever-plc-loss-submission-form?prid=29303&wire=1
According to the filed complaint, a) in July 2020, the board of Ben & Jerry’s, one of Unilever’s marquee brands, passed a resolution to end sales of its ice cream in “Occupied Palestinian Territory” ; and b) this boycott decision risked adverse governmental actions for violations of laws, executive orders, or resolutions aimed at discouraging boycotts, divestment, and sanctions of Israel adopted by 35 U.S. states.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE : Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/706796/CLASS-ACTION-UPDATE-for-AXSM-TDOC-and-UL-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders
